Harrow (HROW) Amortization of Deferred Charges (2017 - 2026)
Harrow's (HROW) quarterly Amortization of Deferred Charges came in at $451000.0 in Q1 2026, down 64.63% year-on-year from $1.3 million in Q1 2025, and up 25.98% quarter-over-quarter from $358000.0 in Q4 2025.
Harrow (HROW) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Harrow's Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $451000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 64.63% year-over-year to $451000.0 in Q1 2026; TTM through Mar 2026 was $1.1 million, a 59.97% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 3.69% from the prior year.
- Amortization of Deferred Charges rose to $451000.0 in Q1 2026 per HROW's latest filing, from $358000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $3.6 million in Q4 2023 and bottomed at $124000.0 in Q1 2022.
- The 5-year median for Amortization of Deferred Charges is $197000.0 (2022), against an average of $631529.4.
- Across the five-year window, Amortization of Deferred Charges soared 1705.08% in 2023 and slumped 70.66% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $197000.0 in 2022, then surged by 1705.08% to $3.6 million in 2023, then plunged by 65.69% to $1.2 million in 2024, then slumped by 70.66% to $358000.0 in 2025, then gained by 25.98% to $451000.0 in 2026.
- Per Business Quant, the three latest HROW Amortization of Deferred Charges figures stand at $451000.0 (Q1 2026), $358000.0 (Q4 2025), and $145000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn |
| 10 | Harrow | 1.42 Bn | 1.32 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 451,000.00 |
| Mar 31, 2026 | 451,000.00 |
| Dec 31, 2025 | 358,000.00 |
| Dec 31, 2025 | 358,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Sep 30, 2025 | 145,000.00 |
| Jun 30, 2025 | 195,000.00 |
| Jun 30, 2025 | 195,000.00 |
| Mar 31, 2025 | 1.28 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 197,000.00 |
| Sep 30, 2024 | 197,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 178,000.00 |
| Mar 31, 2024 | 976,000.00 |
| Mar 31, 2024 | 976,000.00 |
| Dec 31, 2023 | 3.56 Mn |
| Dec 31, 2023 | 3.56 Mn |